| Revenue growth | 24% YoY growth to ₹1,341 million driven by better product mix. |
|---|---|
| Margins | EBITDA margin at 21%; guided 20-22% range for next fiscal. |
| Order book | Orders becoming more stable; consistent flow from key end-use segments. |
| Demand visibility | Consistent gradual uptick in demand; customer interactions moving to long-term. |
| Management confidence | Balanced, highlighting operational milestones while acknowledging geopolitical cost pressures. |
Growth
Revenue grew 24% YoY to ₹1,341 million; EBITDA rose 214% YoY due to better product mix and operating leverage.
Outlook
Guided FY27 revenue growth of 25% with margins between 20-22%; Dahej plant reaching full utilization.
Risks
High ammonia and crude derivative costs; potential shipping delays from Middle East conflicts; high debt levels mentioned.
Earnings Call filed with NSE, NSE: TATVA. Summary written with AI assistance from the document.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,991.20
- Market cap
- ₹4,658 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 90.7×Sector 36.8×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 3.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Tatva Chintan Pharma Chem Annual Report
Tatva Chintan Pharma Chem Limited has submitted its Annual Report for the financial year 2025-26. The company's 30th Annual General Meeting is scheduled for September 25, 2026.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited has scheduled its 30th Annual General Meeting for September 25, 2026. Key agenda items include dividend declaration and director re-appointments.
Tatva Chintan Pharma Chem Annual General Meeting
Tatva Chintan Pharma Chem Limited scheduled its 30th AGM for September 25, 2026. Key agenda items include dividend declaration and increasing borrowing limits to ₹1,000 Crore.
- Value
- ₹1,000 Cr